ANI Pharma director granted 11,116 shares

Q: What is the vesting schedule for Shanmugam Muthusamy’s 11,116-share award at ANI Pharmaceuticals?

The 11,116-share restricted stock award will vest in four equal annual installments. Vesting occurs on the first, second, third and fourth anniversaries of February 26, 2026, aligning long-term incentives with continued service and potential company performance over several years.

Shanmugam Muthusamy reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/02/2026 - 05:59 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Shanmugam Muthusamy reported acquisition or exercise transactions in this Form 4 filing.

ANI Pharmaceuticals director and executive Shanmugam Muthusamy received a grant of 11,116 shares of common stock as a restricted stock award. The award was granted on February 26, 2026 at $77.15 per share and will vest in four equal annual installments on the first, second, third and fourth anniversaries of that date.

After this grant, he directly holds 101,056 common shares. He also has indirect ownership over 431,920 shares held by Esjay LLC and 5,000 shares held by SS Pharma LLC, where he holds voting and dispositive power over the shares.

Insider Trade Summary

Grant/Award: 11,116 shares

Grant/Award 1 txn

Insider Shanmugam Muthusamy

Role HEAD OF R&D, COO-NOVITIUM OPS

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	11,116	$77.15	$858K
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 101,056 shares (Direct); Common Stock — 431,920 shares (Indirect, Held by Esjay LLC); Common Stock — 5,000 shares (Indirect, Held by SS Pharma LLC)

Holdings Before and After: Common Stock, 89,940 to 101,056 shares (Direct)

Footnotes (3)

F1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.
F2. The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
F3. The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANI Pharmaceuticals (ANIP) report for Shanmugam Muthusamy?

ANI Pharmaceuticals reported that executive and director Shanmugam Muthusamy received a grant of 11,116 shares of common stock. The filing describes this as a restricted stock award, reflecting equity-based executive compensation rather than an open-market stock purchase or sale.

How many shares were granted to Shanmugam Muthusamy in the latest ANIP Form 4?

The Form 4 shows a restricted stock grant of 11,116 shares of ANI Pharmaceuticals common stock. These shares were valued at $77.15 per share on the grant date, representing a significant equity award tied to his role as head of R&D and COO-Novitium operations.

How many ANI Pharmaceuticals shares does Shanmugam Muthusamy own directly after this grant?

After the restricted stock grant, Shanmugam Muthusamy directly holds 101,056 shares of ANI Pharmaceuticals common stock. This direct holding figure reflects his personal ownership position, separate from additional shares held indirectly through related limited liability companies.

What indirect shareholdings in ANI Pharmaceuticals are associated with Shanmugam Muthusamy?

Indirectly, 431,920 shares are held by Esjay LLC and 5,000 shares by SS Pharma LLC. The Form 4 notes that Shanmugam Muthusamy holds voting and dispositive power over shares in both entities, giving him effective control over those indirect positions.

Was the ANI Pharmaceuticals Form 4 transaction a purchase or a grant of shares?

The Form 4 describes the transaction as a grant or award, not an open-market purchase. It is coded as an acquisition of 11,116 shares through a restricted stock award, highlighting equity-based compensation rather than a typical insider buying or selling transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shanmugam Muthusamy

(Last)

(First)

(Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE

56623

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	HEAD OF R&D, COO-NOVITIUM OPS

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/26/2026		A⁽¹⁾		11,116	A	$77.15	101,056	D
Common Stock								431,920	I	Held by Esjay LLC⁽²⁾
Common Stock								5,000	I	Held by SS Pharma LLC⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026.

2. The reporting person holds voting and dispositive power over the shares held by Esjay LLC.

3. The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.

Remarks:

	/s/ Muthusamy Shanmugam, by attorney-in-fact Meredith W. Cook	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR